GIPR and obesity disorder: Recently, Amgen have completed a phase 1 trial of a GLP-1R mimetic–GIPR antibody conjugate molecule, termed AMG133, which elicited a 15% reduction in body weight over 85 days in its cohort of participants with obesity when administered at the highest dose of 420 mg monthly (Véniant et al. 2024, clinical trial identifier: NCT04478708).